Retraction notice to “Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients” (Pharmacol. Res. (2013) 73 (20–26) (S104366181300073X) (10.1016/j.phrs.2013.04.005));Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients

Pharmacological Research

Volumn 73, Issue , 2013, Pages 20-26

  Derosa, Giuseppe ^a   Ragonesi, Pietro D ^b   Carbone, Anna ^c   Fogari, Elena ^a   D'Angelo, Angela ^a   Cicero, Arrigo F G ^d   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b SAN CARLO BORROMEO HOSPITAL   (Italy)

^c Hospital Center of Diabetes   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Insulin resistance; Metformin; Omentin 1; Vaspin; Vildagliptin; Visfatin

Indexed keywords

ARGININE; C PEPTIDE; CARRIER PROTEIN; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OMENTIN 1; PLACEBO; PROINSULIN; UNCLASSIFIED DRUG; VASPIN; VILDAGLIPTIN;

ADULT; AMINO ACID TRANSPORT; ARTICLE; B LYMPHOCYTE; BODY MASS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT BETA CELL FUNCTION INDEX; HOMEOSTASIS MODEL ASSESSMENT INSULIN RESISTANCE INDEX; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING; WEIGHT REDUCTION;

EID: 84878380125     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.05.027     Document Type: Erratum

References (34)

1. G.C. Weir, and J.L. Leahy Pathogenesis of non-insulin-dependent (type II) diabetes mellitus C.R. Kahn, G.E. Weir, Joslin's diabetes mellitus 13th ed. 1994 Lea & Febiger Philadelphia, PA 240 264
2. C. Bogardus Metabolic abnormalities in the development of non-insulin-dependent diabetes mellitus D. LeRoith, S.I. Taylor, J.M. Olefski, Diabetes mellitus 1996 Lippincot-Raven Publishers Philadelphia, PA 459
3. R.A. DeFronzo Lilly Lecture 1987. The triumvirate: B-cell, muscle, liver: a collision responsible for NIDDM Diabetes 37 1988 667 687
4. C. Weyer, C. Bogardus, D.M. Mott, and R.E. Pratley The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus Journal of Clinical Investigation 104 6 1999 787 794
5. D.M. Nathan, J.B. Buse, M.B. Davidson, E. Ferrannini, R.R. Holman, and R. Sherwin American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 2009 193 203
6. G. Derosa, and P. Maffioli Dipeptidyl peptidase-4 inhibitors: 3 years of experience Diabetes Technology and Therapeutics 14 4 2012 350 364
7. G. Derosa, and P. Maffioli Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes Diabetes, Metabolic Syndrome and Obesity 4 2011 263 271
8. G. Derosa, P. Maffioli, I. Ferrari, R. Mereu, P.D. Ragonesi, and F. Querci Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients Hormone and Metabolic Research 42 9 2010 663 669
9. G. Derosa, P. Maffioli, S.A. Salvadeo, I. Ferrari, P.D. Ragonesi, and F. Querci Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients Metabolism: Clinical and Experimental 59 6 2010 887 895
10. L. Rydén, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, and M.J. de Boer Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) European Heart Journal 28 1 2007 88 136
11. A.H. Lichtenstein, L.J. Appel, M. Brands, M. Carnethon, S. Daniels, and H.A. Franch Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006 Arteriosclerosis, Thrombosis, and Vascular Biology 26 2006 2186 2191
12. H.F. Bunn, K.H. Gabbay, and P.M. Gallop The glycosylation of haemoglobin: relevance to diabetes mellitus Science 200 1978 21 27
13. European Diabetes Policy Group A desktop guide to type 2 diabetes mellitus Diabetic Medicine 16 1999 716 730
14. L.G. Heding Determination of total serum insulin (IRI) in insulin-treated diabetic patients Diabetologia 8 1972 260 266
15. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
16. T.M. Wallace, J.C. Levy, and D.R. Matthews Use and abuse of HOMA modeling Diabetes Care 27 2004 1487 1495
17. P. Houssa, B. Dinensen, M. Deberg, B.H. Frank, C. Van Schravendijk, and F. Sodoyez-Goffaux First direct assay for intact human proinsulin Clinical Chemistry 44 7 1998 1514 1519
18. H. El Kenz, and P. Bergmann Evaluation of immunochemiluminometric assays for the measurement of insulin and C-peptide using the ADVIA Centaur Clinical Laboratory 50 2004 171 174
19. J.J. Holst Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin Biochemical Journal 207 1982 381 388
20. K. Hida, J. Wada, J. Eguchi, H. Zhang, M. Baba, and A. Seida Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity Proceedings of the National Academy of Sciences of the United States of America 102 2005 10610 10615
21. A. Körner, A. Garten, M. Blüher, R. Tauscher, J. Kratzsch, and W. Kiess Molecular characteristics of serum visfatin and differential detection by immunoassays Journal of Clinical Endocrinology and Metabolism 92 12 2007 4783 4791
22. C.M. De Souza Batista, R.Z. Yang, M.J. Lee, N.M. Glynn, D.Z. Yu, and J. Pray Omentin plasma levels and gene expression are decreased in obesity Diabetes 56 6 2007 1655 1661
23. R.A. DeFronzo, J.D. Tobin, and R. Andres Glucose clamp technique: a method for quantifying insulin secretion and resistance American Journal of Physiology 237 1979 E214 E223
24. M.C. Bunck, M. Diamant, A. Cornér, B. Eliasson, J.L. Malloy, and R.M. Shaginian One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial Diabetes Care 32 2009 762 768
25. P. Fasching, K. Ratheiser, P. Nowotny, S. Uurzemann, S. Parker, and W. Waldhaus Insulin production following intravenous glucose, arginine, and valine: different pattern in patients with impaired glucose tolerance and non-insulin-dependent diabetes mellitus Metabolism: Clinical and Experimental 43 1994 385 389
26. B.J. Winer Statistical principles in experimental design 2nd ed. 1971 McGraw-Hill New York
27. B.S. Youn, N. Klöting, J. Kratzsch, N. Lee, J.W. Park, and E.S. Song Serum vaspin concentrations in human obesity and type 2 diabetes Diabetes 57 2 2008 372 377
28. H.O. El-Mesallamy, D.H. Kassem, E. El-Demerdash, and A.I. Amin Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus Metabolism: Clinical and Experimental 60 1 2011 63 70
29. A. Fukuhara, M. Matsuda, M. Nishizawa, K. Segawa, M. Tanaka, and K. Kishimoto Visfatin: a protein secreted by visceral fat that mimics the effects of insulin Science 307 5708 2005 426 430
30. C. Hug, H.F. Lodish, and Medicine Visfatin: a new adipokine Science 307 5708 2005 366 367
31. R.Z. Yang, M.J. Lee, H. Hu, J. Pray, H.B. Wu, and B.C. Hansen Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action American Journal of Physiology - Endocrinology and Metabolism 290 6 2006 E1253 E1261
32. A. Schäffler, M. Neumeier, H. Herfarth, A. Fürst, J. Schölmerich, and C. Büchler Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue Biochimica et Biophysica Acta 1732 1-3 2005 96 102
33. S. Kralisch, J. Klein, M. Bluher, R. Paschke, M. Stumvoll, and M. Fasshauer Therapeutic perspectives of adipocytokines Expert Opinion on Pharmacotherapy 6 2005 863 872
34. B.K. Tan, R. Adya, S. Farhatullah, K.C. Lewandowski, P. O'Hare, and H. Lehnert Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose Diabetes 57 4 2008 801 808